Danske Bank A S Sells 61,471 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Danske Bank A/S slashed its Halozyme stake by 97.9% in Q4, selling 61,471 shares and leaving it with just 1,300 shares worth about $87,000.
• Company insiders have been net sellers — CEO Helen Torley sold 20,000 shares for roughly $1.285M under a Rule 10b5‑1 plan, directors also sold, and insiders disposed of 90,482 shares (~$6.07M) in the past 90 days, leaving insiders with 2.50% ownership.
• Halozyme posted an unexpected quarterly EPS loss of ($0.24) versus a $1.92 consensus while revenue rose 51.6% to $451.8M, and analysts' consensus rating is a Hold with a $79.11 price target.

Danske Bank A S lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 97.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,300 shares of the biopharmaceutical company's stock after selling 61,471 shares during the quarter. Danske Bank A S's holdings in Halozyme Therapeutics were worth $87,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of HALO. Root Financial Partners LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter worth $25,000. Larson Financial Group LLC grew its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 343 shares during the last quarter. Richardson Financial Services Inc. grew its position in Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 198 shares during the last quarter. Clearstead Advisors LLC grew its position in Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 265 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter worth $52,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at $49,322,187.20. This trade represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the transaction, the director directly owned 38,498 shares of the company's stock, valued at $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 90,482 shares of company stock valued at $6,073,942 in the last ninety days. Insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Wall Street Zen lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Saturday, February 21st. HC Wainwright lifted their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, April 29th. Weiss Ratings lowered shares of Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a research report on Tuesday, February 24th. TD Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Finally, Benchmark lifted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $79.11.

Halozyme Therapeutics Trading Down 1.7%

Shares of HALO stock opened at $65.19 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22. The company has a market capitalization of $7.72 billion, a P/E ratio of 26.18, a P/E/G ratio of 0.27 and a beta of 0.89. The firm has a 50-day moving average price of $65.86 and a 200 day moving average price of $68.59. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same period in the prior year, the business earned $1.26 earnings per share. The company's revenue for the quarter was up 51.6% on a year-over-year basis. Research analysts forecast that Halozyme Therapeutics, Inc. will post 7.68 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.